{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:29:11Z","timestamp":1770596951909,"version":"3.49.0"},"reference-count":59,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundaci\u00f3n IMSS","award":["R-2021-1305-007"],"award-info":[{"award-number":["R-2021-1305-007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Uric acid (UA) and the markers of mineral bone metabolism and inflammation are commonly altered in patients with chronic kidney disease (CKD) and are associated with the risk of cardiovascular complications and death. Studies point to a link between high serum UA and mineral bone homeostasis and inflammation, but controversy remains. The aim of this study was to evaluate the relationship between UA levels and mineral bone metabolism and inflammation biomarkers in a sample of Mexican patients with CKD 3a\u20135. Materials and Methods: This cross-sectional study included 146 Mexican patients with CKD 3a\u20135. In addition, 25 healthy subjects were included in the study with the aim of generating reference data for comparisons. Metabolic parameters including UA serum concentrations, mineral bone metabolism (parathormone (PTH), fibroblast growth factor 23 (FGF23), calcium, and phosphate), and inflammation (interleukin (IL)-1\u03b2, IL-6, and tumor necrosis factor-alpha (TNF-\u03b1)) biomarkers were measured in all of the samples and compared as a function of the estimated glomerular function rate (eGFR) or UA levels. Results: Intact PTH, FGF23, and cytokines were higher in advanced CKD stages. Patients with hyperuricemia had significantly higher values of FGF23 and TNF-\u03b1 compared with those without hyperuricemia. The eGFR was found to be significantly and negatively correlated with all markers. Uric acid was significantly correlated with phosphate, iPTH, FGF23, and TNF-\u03b1, whereas iPTH was significantly correlated with FGF23, TNF-\u03b1, and FGF23. Finally, a multivariate analysis confirmed the relationship of eGFR with all the tested biomarkers, as well as other relationships of iPTH with UA and TNF-\u03b1 and of FGF23 with UA and TNF-\u03b1. Conclusions: This study supports the relationship between uric acid and levels of mineral bone metabolism and inflammation biomarkers in patients with CKD at middle to advanced stages. In the follow-up of patients with CKD, monitoring and controlling UA levels through nutritional or pharmacological interventions could help in the prevention of alterations related to mineral bone metabolism.<\/jats:p>","DOI":"10.3390\/medicina60122081","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T03:59:43Z","timestamp":1734580783000},"page":"2081","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Uric Acid Correlates with Serum Levels of Mineral Bone Metabolism and Inflammation Biomarkers in Patients with Stage 3a\u20135 Chronic Kidney Disease"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0786-988X","authenticated-orcid":false,"given":"Francisco","family":"Mendoza Carrera","sequence":"first","affiliation":[{"name":"Divisi\u00f3n de Medicina Molecular, Centro de Investigaci\u00f3n Biom\u00e9dica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria Elizabeth","family":"V\u00e1zquez Rivera","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Medicina Molecular, Centro de Investigaci\u00f3n Biom\u00e9dica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caridad A.","family":"Leal Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Investigaci\u00f3n Quir\u00fargica, Centro de Investigaci\u00f3n Biom\u00e9dica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes del Carmen","family":"Rizo De la Torre","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Medicina Molecular, Centro de Investigaci\u00f3n Biom\u00e9dica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3408-4719","authenticated-orcid":false,"given":"Renato","family":"Parra Michel","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, Hospital General Regional No. 46, Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44910, Jalisco, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalba","family":"Orozco Sandoval","sequence":"additional","affiliation":[{"name":"Unidad de Medicina Familiar No. 3, Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"P\u00e9rez Coria","sequence":"additional","affiliation":[{"name":"Divisi\u00f3n de Medicina Molecular, Centro de Investigaci\u00f3n Biom\u00e9dica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic Kidney Disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"KDIGO 2013 (2013). Chapter 1: Definition and classification of CKD. Kidney Int. Suppl., 3, 19\u201362.","DOI":"10.1038\/kisup.2012.64"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10157-022-02216-x","article-title":"Emerging cross-talks between chronic kidney disease-mineral and bone disorder (CKD-MBD) and malnutrition-inflammation complex syndrome (MICS) in patients receiving dialysis","volume":"26","author":"Yamada","year":"2022","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1080\/0886022X.2022.2107543","article-title":"Mineral and bone disorder and longterm survival in a chronic kidney disease grade 3b-4cohort","volume":"44","author":"Rios","year":"2022","journal-title":"Ren. Fail."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/ndt\/gfs460","article-title":"Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: A sequence suggested from a cross-sectional study","volume":"28","author":"Pavik","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.kint.2021.07.013","article-title":"Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease","volume":"100","author":"Mehta","year":"2021","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11914-021-00703-w","article-title":"Regulation of FGF23: Beyond Bone","volume":"19","author":"Simic","year":"2021","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e74782","DOI":"10.7554\/eLife.74782","article-title":"Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling","volume":"11","author":"Czaya","year":"2022","journal-title":"Elife"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Song, T., Fu, Y., Wang, Y., Li, W., Zhao, J., Wang, X., Wang, H., Zhao, Y., and Fu, X. (2021). FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-020-01839-w"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1814304","DOI":"10.1155\/2019\/1814304","article-title":"Inflammation-related patterns in the clinical staging and severity assessment of chronic kidney disease","volume":"2019","author":"Mihai","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Mace, M.L., Egstrand, S., Morevati, M., Olgaard, K., and Lewin, E. (2021). New insights to the crosstalk between vascular and bone tissue in chronic kidney disease-mineral and bone disorder. Metabolites, 11.","DOI":"10.3390\/metabo11120849"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Abinti, M., Vettoretti, S., Caldiroli, L., Mattinzoli, D., Ikehata, M., Armelloni, S., Molinari, P., Alfieri, C.M., Castellano, G., and Messa, P. (2024). Associations of intact and C-Terminal FGF23 with inflammatory markers in older patients affected by advanced chronic kidney disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133967"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s00467-020-04843-6","article-title":"Fibroblast growth factor 23-Klotho and hypertension: Experimental and clinical mechanisms","volume":"36","author":"Freundlich","year":"2021","journal-title":"Pediatr. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/jbmr.4003","article-title":"IL-1beta Drives Production of FGF-23 at the Onset of Chronic Kidney Disease in Mice","volume":"35","author":"McKnight","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wang, H., Chen, Y., Gou, Y., Yang, D., and Xiong, L. (2024). Chronic kidney diseases and inflammation research: A bibliometric analysis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1388665"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1681\/ASN.V1271549","article-title":"The microinflammatory state in uremia: Causes and potential consequences","volume":"12","author":"Kaysen","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lee, T.H., Chen, J.J., Wu, C.Y., Yang, C.W., and Yang, H.Y. (2021). Hyperuricemia and progression of chronic kidney disease: A review from physiology and pathogenesis to the role of urate-lowering therapy. Diagnostics, 11.","DOI":"10.3390\/diagnostics11091674"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ekir.2022.11.016","article-title":"Uric acid and chronic kidney disease: Still more to do","volume":"8","author":"Johnson","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/ndt\/gfv024","article-title":"Hyperuricemia-induced inflammasome and kidney diseases","volume":"31","author":"Isaka","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lin, K.M., Lu, C.L., Hung, K.C., Wu, P.C., Pan, C.F., Wu, C.J., Syu, R.S., Chen, J.S., Hsiao, P.J., and Lu, K.C. (2019). The paradoxical role of uric acid in osteoporosis. Nutrients, 11.","DOI":"10.3390\/nu11092111"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e230040","DOI":"10.1530\/EC-23-0040","article-title":"Relationship between serum uric acid levels and osteoporosis","volume":"12","author":"Xu","year":"2023","journal-title":"Endocr. Connect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/1756-185X.13740","article-title":"Primary hyperparathyroidism is associated with a higher level of serum uric acid: A systematic review and meta-analysis","volume":"23","author":"Ponvilawan","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000512340","article-title":"Serum urate lowering therapy using Allopurinol improves serum 25 hydroxy vitamin D in stage 3-5 CKD patients: A pilot study","volume":"145","author":"Mohammed","year":"2021","journal-title":"Nephron"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000282801","article-title":"Relationship between 1,25-dihydroxyvitamin-D, calcium and uric acid in urinary stone formers","volume":"56","author":"Jarrar","year":"1996","journal-title":"Urol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Thakkinstian, A., Anothaisintawee, T., Chailurkit, L., Ratanachaiwong, W., Yamwong, S., Sritara, P., and Ongphiphadhanakul, B. (2015). Potential causal associations between vitamin D and uric acid: Bidirectional mediation analysis. Sci. Rep., 5.","DOI":"10.1038\/srep14528"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00198-019-05072-w","article-title":"Association between serum uric acid and bone health in adolescents","volume":"30","author":"Karimi","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jocd.2012.05.008","article-title":"Serum uric acid levels in relation to bone-related phenotypes in men and women","volume":"16","author":"Sritara","year":"2013","journal-title":"J. Clin. Densitom."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2147\/CIA.S186500","article-title":"Specific higher levels of serum uric acid might have a protective effect on bone mineral density within a Chinese population over 60 years old: A cross-sectional study from northeast China","volume":"14","author":"Chen","year":"2019","journal-title":"Clin. Interv. Aging"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jeon, H.J., Oh, J., and Shin, D.H. (2019). Urate-lowering agents for asymptomatic hyperuricemia in stage 3\u20134 chronic kidney disease: Controversial role of kidney function. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0218510"},{"key":"ref_32","unstructured":"USRDS (2021). Annual Data Report: Epidemiology of Kidney Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.arcmed.2013.01.008","article-title":"Reaching targets for mineral metabolism clinical practice guidelines and its impact on outcomes among Mexican chronic dialysis patients","volume":"44","author":"Paniagua","year":"2013","journal-title":"Arch. Med. Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Robles-Rivera, K., Argoty-Pantoja, A.D., Hidalgo-Bravo, A., Quezada-Sanchez, A.D., Leon-Reyes, G., Flores, Y.N., Salmeron, J., Velazquez-Cruz, R., and Rivera-Paredez, B. (2022). Uric acid levels are associated with bone mineral density in Mexican populations: A longitudinal study. Nutrients, 14.","DOI":"10.3390\/nu14204245"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: More accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2019). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care, 42, S13\u2013S28.","DOI":"10.2337\/dc19-S002"},{"key":"ref_37","first-page":"e426","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.semnephrol.2020.12.004","article-title":"Hyperuricemia in Kidney Disease: A Major Risk Factor for Cardiovascular Events, Vascular Calcification, and Renal Damage","volume":"40","author":"Ejaz","year":"2020","journal-title":"Sem. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Andrews, E.S., Perrenoud, L., Nowak, K.L., You, Z., Pasch, A., Chonchol, M., Kendrick, J., and Jalal, D. (2018). Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205831"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2147\/CIA.S90233","article-title":"Significant association between parathyroid hormone and uric acid level in men","volume":"10","author":"Chin","year":"2015","journal-title":"Clin. Interv. Aging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1007\/s11255-022-03116-5","article-title":"Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease","volume":"54","author":"Costa","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00198-011-1776-x","article-title":"Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey","volume":"23","author":"Paik","year":"2012","journal-title":"Osteoporos. Int."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Yang, R., Ding, N., Qin, J., and Peng, H. (2024). The relationship between uric acid and bone mineral density in the intermediate stage of CKD 1-3. BMC Nephrol., 25.","DOI":"10.1186\/s12882-024-03650-7"},{"key":"ref_44","first-page":"149","article-title":"PTH levels and not serum phosphorus levels are a predictor of the progression of kidney disease in elderly patients with advanced chronic kidney disease","volume":"37","year":"2017","journal-title":"Nefrologia"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Peng, H., Li, H., Li, C., Chao, X., Zhang, Q., and Zhang, Y. (2013). Association between vitamin D insufficiency and elevated serum uric acid among middle-aged and elderly Chinese Han women. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061159"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Halperin Kuhns, V.L., and Woodward, O.M. (2020). Sex Differences in Urate Handling. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124269"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/MNH.0000000000000793","article-title":"Contribution of phosphate and FGF23 to CKD progression","volume":"31","author":"Jansson","year":"2022","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1681\/ASN.2017070772","article-title":"Longitudinal FGF23 Trajectories and Mortality in Patients with CKD","volume":"29","author":"Isakova","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.kint.2016.10.021","article-title":"Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease","volume":"91","author":"Isakova","year":"2017","journal-title":"Kidney Int."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wang, H., and Chen, P. (2020). Higher fibroblast growth factor 23 levels are causally associated with lower bone mineral density of heel and femoral Neck: Evidence from two-sample mendelian randomization Analysis. Front. Public. Health, 8.","DOI":"10.3389\/fpubh.2020.00467"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/eci.12677","article-title":"Hyperuricemia protects against low bone mineral density, osteoporosis and fractures: A systematic review and meta-analysis","volume":"46","author":"Veronese","year":"2016","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Liu, H., Xie, R., Dai, Q., Fang, J., Xu, Y., and Li, B. (2023). Exploring the mechanism underlying hyperuricemia using comprehensive research on multi-omics. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-34426-y"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.semarthrit.2020.04.007","article-title":"The biology of urate","volume":"50","author":"Keenan","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e13108","DOI":"10.1097\/MD.0000000000013108","article-title":"Relationship between oxidative stress and inflammation in hyperuricemia: Analysis based on asymptomatic young patients with primary hyperuricemia","volume":"97","author":"Zhou","year":"2018","journal-title":"Medicine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e23949","DOI":"10.1002\/jcla.23949","article-title":"The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia","volume":"35","author":"Wu","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2217\/pgs.15.52","article-title":"URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia","volume":"16","author":"Sun","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Perdomo-Ramirez, A., Cordoba-Lanus, E., Trujillo-Frias, C.J., Gonzalez-Navasa, C., Ramos-Trujillo, E., Luis-Yanes, M.I., Garcia-Nieto, V., and Claverie-Martin, F. (2023). Pathogenic variants of SLC22A12 (URAT1) and SLC2A9 (GLUT9) in Spanish patients with renal hypouricemia: Founder effect of SLC2A9 variant c.374C>T; p.(T125M). Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098455"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/12\/2081\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:55:20Z","timestamp":1760115320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/12\/2081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":59,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["medicina60122081"],"URL":"https:\/\/doi.org\/10.3390\/medicina60122081","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}